AMENDMENTS TO THE CLAIMS

Claims 1 to 27 (cancelled)

Claim 28 (currently amended)

A compound of the formula



III

wherein R_3 is selected from the group consisting of hydrogen, methyl and –OH,

R_4 is hydrogen or –OH,

T is ~~selected from the group consisting of~~ hydrogen, ~~methyl, CH_2CONH_2, CH_2CN, $(CH_2)_2NH_2$ and $(CH_2)_2Nalk_2^+X^-$, alk is alkyl of 1 to 8 carbon atoms, X^- is halogen,~~

Y is selected from the group consisting of hydrogen, -OH, halogen and $-OSO_2H$ and salts thereof, W is hydrogen, ~~or -OH,~~

Z is hydrogen or methyl or a non-toxic pharmaceutically acceptable acid addition salt thereof.

Claim 29 (currently amended)

A compound of claim ~~28~~ 31 selected from the group consisting of

1-([-4-oxo-N2-(12-methyl-1-oxotetradecyl)-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B,

1-[N2-[[4'-octyloxy)-[1,1'-biphenyl]-4-yl]-carbonyl]-4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B,

1-[N2-[[4-[4-[4-(pentyloxy)phenyl]-1-piperazinyl]-phenyl]-carbonyl]4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B.

Claim 30 (currently amended)

A compound of claim 28 of the formula



III

Claim 31 (currently amended)

A compound of the formula



II

wherein R is selected form the group consisting of alkyl and cycloalkyl of up to 30 carbon atoms optionally containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, at least one heterocycle and acyl of up to 30 carbon atoms optionally containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen and/or at least one heterocycle,

R_3 is selected from the group consisting of hydrogen, methyl and –OH,

R_4 is hydrogen or –OH,

T is selected from the group consisting of hydrogen, methyl, $-CH_2-CONH_2-$, $-CH_2-CN$, $-(CH_2)_2-NH_2$ and $-(CH_2)_2-Nalk_2^+X^-$, alk is alkyl of 1 to 8 carbon atoms, X^- is halogen,

Y is selected from the group consisting of hydrogen, -OH, halogen and –OSO$_3$H and salts thereof, W is hydrogen, or –OH,

Z is hydrogen or methyl or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Claim 32 (cancelled)

Claim 33 (currently amended)

A compound of the formula



IV

wherein R is selected from the group consisting of alkyl and cycloalkyl of up to 30

carbon atoms optionally containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, at least one hetercycle and acyl of up to 30 carbon atoms optionally containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen and/or at least one heterocycle,

R_3 is selected from the group consisting of hydrogen, methyl and –OH,

R_4 is hydrogen or –OH,

T is ~~selected from the group consisting of~~ hydrogen, ~~methyl, CH_2-$CONH_2$-, CH_2-CN, $(CH_2)_2$-NH_2 and $(CH_2)_2$-$Nalk_2^+X^-$, alk is alkyl of 1 to 8 carbon atoms, X^- is halogen,~~

Y is selected from the group consisting of hydrogen, -OH, halogen and –$\underline{O}SO_3H$ and salts thereof, W is hydrogen, ~~or OH,~~

Z is hydrogen or methyl or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Claim 34 (previously presented)

A method of treating an ailment in people caused by exposure to a fungus comprising administering to people in need thereof an antifungally effective amount of an echinocandin B derivative or its acid addition salt.

Claim 35 (previously presented)

The method of claim 34 in which said fungus is selected from the group consisting of *Candida albicans, Candida glabrate, krusei, tropicalis, pseudotropicalis, parapsilosis, Aspergillus fumigatus, Aspergillus flavus,* and *Cryptococcus neoformans.*

Claim 36 (previously presented)

The method of claim 34 in which said ailment is selected from the group consisting of digestive, urinary, vaginal or cutaneous candidoses, cryptococcoses, neuromenengeal, pulmonary or cutaneous cyrptococcoses, bronchopulmonary and pulmonary aspergilloses and invasive aspergilloses of immunocompromise.

Claim 37 (previously presented)

The method of claim 34 which is directed to the prevention of mycosic ailments in people with congenital or acquired immune compromise.

Claim 38 (previously presented)

The method of claim 34 in which said derivative of echinocandin B or its acid addition salt is administered in the form of an injectable preparation.

Claim 39 (previously presented)

The method of claim 34 in which said derivative of echinocandin B or its acid addition salt is administered in the form of a solution.

Claim 40 (previously presented)

The method of claim 34 in which the effective amount ranges from about 50 mg to about 300 mg per day.

Claim 41 (previously presented)

The method of claim 39 in which said solution is obtained by dissolving a powder of said derivative of echinocandin B or its acid addition salt in an appropriate medium.

Claim 42 (previously presented)

The method of claim 41 in which said appropriate medium comprises apyrogenic sterile water.

Claim 43 (previously presented)

A compound of the formula:



wherein

R1 is hydrogen,

R2 is an alkyl of two carbons interrupted with



a and b are each hydrogen,

R3 is methyl,

R4 is –OH,

R is



T, Y and W are each hydrogen, and

Z is methyl or

a pharmaceutically acceptable acid addition salt thereof.

Claim 44 (new)

A compound of claim 33 wherein R is C(O)-Ph-Ph-OC_8H_{17}.

Claim 45 (new)

A compound of claim 33 wherein Z is methyl.

Claim 46 (new)

A compound of claim 33 wherein Y is hydrogen.

Claim 47 (new)

A compound of claim 33 wherein R^3 is methyl.

Claim 48 (new)

A compound of claim 33 wherein R^4 is hydroxyl.

Claim 49 (new)

A compound of claim 33 of the following formula: